Skip to main content

Table 2 Relationship between the expression of TIM-3 and clinicopathological parameters

From: Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma

  TIM-3 P value
Positive Negative
Total 92 (56.4) 71 (43.6)  
Age, n (%)    0.987
 < 70y 83 (90.2) 64 (90.1)  
 ≥ 70y 9 (9.8) 7 (9.9)  
Gender, n (%)    0.259
 Male 57 (53.3) 50 (46.7)  
 Female 35 (62.5) 21 (37.5)  
ISUP, n (%)    0.055
 < 4 67 (79.8) 40 (65.6)  
 ≥ 4 17 (20.2) 21 (34.4)  
Histological Type, n(%)    0.377
 ccRCC 74 (58.3) 53 (41.7)  
 Non-ccRCC 18 (50.0) 18 (50.0)  
Pathology, n (%)
 Sarcoma 5 (62.5) 3 (37.5) 0.898
 Necrosis 20 (66.7) 10 (33.3) 0.958
Nephrectomy    0.026
 Yes 84 (61.3) 53 (38.7)  
 No 7 (35.0) 13 (65.0)  
ECOG, n (%)    0.239
 0–1 68 (60.7) 44 (39.3)  
 ≥ 2 20 (50.0) 20 (50.0)  
IMDC, n (%)    0.030
 Low 23 (69.7) 10 (30.3)  
 Intermediate 49 (61.3) 31 (38.7)  
 High 11 (37.9) 18 (62.1)  
T stage, n (%)    0.391
 < 2b 38 (64.4) 20 (55.6)  
 ≥ 2b 21 (35.6) 16 (44.4)  
Treatment, n (%)
 Cytokine 12 (54.5) 10 (45.5) 0.762
 Targeted therapy 32 (50.0) 32 (50.0) 0.088
 Radiotherapy 7 (50.0) 7 (50.0) 0.504
 Chemotherapy 5 (62.5) 3 (37.5) 0.817